Important note: Information in this article was accurate in July 2002. The state of the art may have changed since the publication date.AIDSWEEKLY Plus; July 15, 2002
Michael Greer, Senior Medical Writer
"HIV-1 infection is associated with an increased incidence of and mortality from tuberculosis," explained Dr. Remonie Seng and colleagues in working with the Projecto de Saude Bandim, Raoul Follereau Hospital, and the National Public Health Laboratory in Bissau, Guinea-Bissau, the Statens Serum Institute in Copenhagen, Bichat and Saint Antoine Hospitals in Paris, Malmo University Hospital in Malmo, Sweden, and the Swedish Institute for Infectious Disease Control in Stockholm. "Few community studies have examined the effect of HIV-2 on tuberculosis."
HIV-2 infection was associated with a higher tuberculosis risk although the effects of HIV-2 paled in comparison to those of its counterpart, Seng and coauthors found.
The researchers evaluated the effects of tuberculosis and HIV-1 and -2 coinfection in more than 360 patients treated in Bissau, Guinea-Bissau's capital city. HIV-2 infection is more common in Bissau than anywhere else in the world, they noted.
Patients infected with HIV-2 had tuberculosis rates three times higher than HIV- subjects, study data showed. However, the presence of HIV-2 infection had no significant impact on short-term tuberculosis mortality rates.
By contrast, HIV-1 infection increased the tuberculosis risk by more than 18 times, while patients infected with both HIV strains suffered a nearly 14-fold elevation in tuberculosis risk (Community study of the relative impact of HIV-1 and HIV-2 on intrathoracic tuberculosis, AIDS 2002 May 3;16(7):1059-66.
"The presence of HIV-2 infection increases the incidence of tuberculosis compared with that in non-HIV-infected individuals, but does not affect tuberculosis-related mortality in the short term," Seng and colleagues concluded.
The corresponding author for this report is Per Gustafson, Malmo University Hospital, UMAS, Dept. of Infectious Diseases, SE-20502 Malmo, Sweden.
Key points reported in this study include:
This article was prepared by AIDS Weekly editors from staff and other reports.
020715
AW020708
Copyright © 2002 - Charles Henderson, Publisher. All rights Reserved. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633-4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX: (205) 995-1588 http://www.newsrx.net
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, iMetrikus, Inc., the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2002. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright © 1980,2002. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.